Forward looking statement

All statements contained in this presentation, other than statements of historic fact, are forward-looking statements, including statements related to preliminary unaudited 2018 financial information with respect to 2018 net product revenue of Translarna for the treatment of nmDMD and EMFLAZA for the treatment of Duchenne muscular dystrophy, statements with respect to 2019 net product revenue and guidance and statements regarding: the future expectations, plans and prospects for PTC; expectations with respect to PTC’s gene therapy platform, including any potential regulatory submissions; PTC's expectations with respect to the licensing and potential commercialization of Tegsedi and Waylivra; expansion of commercialization of Translarna and Emflaza; advancement of PTC’s joint collaboration program in SMA, including any potential regulatory submissions; PTC’s strategy, future operations, future financial position, future revenues, projected costs; and the objectives of management. Other forward-looking statements may be identified by the words “guidance”, “plan,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions.

PTC’s actual results, performance or achievements could differ materially from those expressed or implied by forward-looking statements it makes as a result of a variety of risks and uncertainties, including those related to: the outcome of pricing, coverage and reimbursement negotiations with third party payors for Emflaza and Translarna and any other product candidates that PTC may commercialize in the future; whether, and to what extent, third party payors impose additional requirements before approving Emflaza prescription reimbursement; PTC’s ability to complete any dystrophin study necessary in order to resolve the matters set forth in the denial to the Complete Response letter it received from the FDA in connection with its new drug application for Translarna for the treatment of nonsense mutation Duchenne muscular dystrophy (nmDMD), and PTC’s ability to perform additional clinical trials, non-clinical studies, and CMC assessments or analyses at significant cost; PTC’s ability to maintain its marketing authorization of Translarna for the treatment of nmDMD in the European Economic Area (EEA), including whether the European Medicines Agency (EMA) determines in future annual renewal cycles that the benefit-risk balance of Translarna authorization supports renewal of such authorization; PTC’s ability to enroll, fund, complete and timely submit to the EMA the results of Study 041, a randomized, 18-month, placebo-controlled clinical trial of Translarna for the treatment of nmDMD followed by an 18-month open-label extension, which is a specific obligation to continued marketing authorization in the EEA; expectations with respect to the potential financial impact or PTC’s ability to realize the anticipated benefits of the acquisition of Agilis and its gene therapy platform, including with respect to the business of Agilis and expectations with respect to the potential achievement of development, regulatory and sales milestones and contingent payments to the former Agilis equityholders with respect thereto and PTC’s ability to obtain marketing approval of PTC-AADC and other product candidates acquired from Agilis, will not be realized or will not be realized within the expected time period; expectations with respect to the potential financial impact and benefits of the collaboration and licensing agreement with Akcea Therapeutics, Inc., including with respect to the timing of regulatory approval of Tegsedi and Waylivra in countries in LATAM and the Caribbean, the commercialization of Tegsedi and Waylivra, and PTC’s expectations with respect to contingent payments to Akcea based on net sales and the potential achievement of regulatory milestones; the enrollment, conduct, and results of studies under the SMA collaboration and events during, or as a result of, the studies that could delay or prevent further development under the program, including any potential regulatory submissions with regards to Risdiplam; PTC’s ability to realize the anticipated benefits of the acquisition of Emflaza, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period; significant transaction costs, unknown liabilities, the risk of litigation and/or regulatory actions related to the acquisition of Emflaza or the acquisition of its gene therapy pipeline, as well as other business effects, including the effects of industry, market, economic, political or regulatory conditions; changes in tax and other laws, regulations, rates and policies; the eligible patient base and commercial potential of Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra, Risdiplam or any of PTC’s other product candidates; PTC’s scientific approach and general development progress; PTC’s ability to satisfy its obligations under the terms of the senior secured term loan facility with MidCap Financial; the sufficiency of PTC’s cash resources and its ability to obtain adequate financing in the future for its foreseeable and unforeseeable operating expenses and capital expenditures; and the factors discussed in the “Risk Factors” section of PTC’s Annual Report on Form 10-K for the year ended December 31, 2017, Quarterly Reports on Form 10-Q for the periods ended March 31, 2018, June 30, 2018 and September 30, 2018 and Exhibit 99.2 to PTC’s Current Report on Form 8-K filed on August 24, 2018, as well as any updates to these risk factors filed from time to time in PTC’s other filings with the SEC. You are urged to carefully consider all such factors.

As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that any product will receive or maintain regulatory approval in any territory, or prove to be commercially successful, including Translarna, Emflaza, PTC-AADC, Tegsedi, Waylivra or Risdiplam.

The forward-looking statements contained herein represent PTC’s views only as of the date of this presentation and PTC does not undertake or plan to update or revise any such forward-looking statements to reflect actual results or changes in plans, prospects, assumptions, estimates or projections, or other circumstances occurring after the date of this presentation except as required by law.
Pipeline evolution: January 2019

Commercial
- AADC Deficiency
- DMD
- *DMD
- Gene Therapy & CNS Programs

Late develop.
- Friedreich Ataxia
- LGMD2i
- Aniridia
- Translarna™ (ataluren)
- Tegsedi™ (inotersen)
- Waylivra™ (volanenorsen)

Early develop.
- Angelman
- Dravet / CDKL5
- Cognitive Disorder

Preclinical
- Cognitive Disorder
- Cognitive Disorder
- Alternative Splicing
- Oncology

Key 2018 Additions
* MA requires annual renewal following reassessment by the European Medicines Agency (EMA)
Looking forward: PTC growth vision for the next 5 years

<table>
<thead>
<tr>
<th>Now</th>
<th>Future</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>COMMERCIAL:</strong></td>
<td><strong>$263M</strong></td>
</tr>
<tr>
<td>2 products (Translarna and Emflaza)</td>
<td></td>
</tr>
<tr>
<td><strong>CLINICAL PROGRAMS:</strong></td>
<td></td>
</tr>
<tr>
<td>(AADC, SMA, Translarna, Emflaza, DIPG, AML)</td>
<td>6</td>
</tr>
<tr>
<td></td>
<td>(AS, DIPG, AML, LMS, HD, FD, +4)</td>
</tr>
<tr>
<td><strong>RESEARCH PROGRAMS:</strong></td>
<td></td>
</tr>
<tr>
<td>(FA, AS, FD, HD, Reelin)</td>
<td>5</td>
</tr>
<tr>
<td></td>
<td>(Small molecules, splicing, gene therapy and others)</td>
</tr>
<tr>
<td><strong>BD:</strong></td>
<td></td>
</tr>
<tr>
<td>Emflaza &amp; Agilis acquisitions, Akcea in-licensing</td>
<td>3</td>
</tr>
</tbody>
</table>
>$1.5B potential revenues to PTC by 2023

* Revenue based on PTC current assumptions and estimates

- Emflaza: ~$90
- Translarna ex-US: ~$170
- Translarna US: ~$300
- Tegsedi & Waylivra: ~$200
- Risdiplam (royalties to PTC): ~$400
- Gene Therapy: ~$300

* Net of royalties
Building a Leading Rare Disorder Biotech Global DMD Franchise
Translarna™: proven track record of performance

- 2018 net product revenue of $171M, an 18% increase over 2017
- Global sales outside of the U.S.
- Pediatric expansion approved in 2018
- Label expansion for non-ambulatory patients under review, decision expected 2019
- U.S. dystrophin study underway, plan to re-submit US NDA in 2020
Emflaza®: Establishing standard of care for all DMD patients in the US

- 2018 Emflaza net product revenue of $91M
- Revenue increase of >$60M over 2017
- Data from multiple publications demonstrate Emflaza’s clinical benefit over prednisone
- July 4th PDUFA for pediatric expansion

Articles

Long-term effects of glucocorticoids on function, quality of life, and survival in patients with Duchenne muscular dystrophy: a prospective cohort study


Summary

Background Glucocorticoid treatment is recommended as a standard of care in Duchenne muscular dystrophy; however, few studies have assessed the long-term benefits of this treatment. We examined the long-term effects of glucocorticoids on milestone-related disease progression across the lifespan and survival in patients with Duchenne muscular dystrophy.

Methods For this prospective cohort study, we enrolled male patients aged 2–28 years with Duchenne muscular dystrophy at 20 centers in nine countries. Patients were followed up for 10 years. We compared no glucocorticoid treatment or cumulative treatment duration of less than 1 month versus treatment of 1 year or longer with regard to progression of nine disease-related and clinically meaningful mobility and upper limb milestones. We used Kaplan-Meier analyses to

milestones by 2.8–8.0 years compared with treatment for less than 1 month. Deflazacort was associated with a median age at loss of three milestones by 2.1–2.7 years in comparison with prednisone or placebo (p<0.012). 45 patients died during the 10-year follow-up. 39 (87%) of these deaths were attributable to

causes in patients with known duration of glucocorticoid usage. 28% deaths occurred in 331 patients treated with glucocorticoids for 1 year or longer compared with 15% deaths in 58 patients with no history of glucocorticoid use (odds ratio 0.47, 95% CI 0.22–0.96, p=0.030).
Driving long-term growth of DMD franchise

Label expansion under review for Translarna™ in non-ambulatory patients by the EMA's NDA for Emflaza® 2-5 year old U.S. patients submitted with potential approval in '19.
An efficient, scalable business engine

- 2019 DMD franchise revenue guidance of $285 - $305M
- Established footprint in >40 countries worldwide
- Experienced commercial and medical teams in orphan disease
- Fully integrated global infrastructure
Building a Leading Rare Disorder Biotech

Leveraging our Global Commercial Franchise
Preventing our rare disease portfolio and revenues.

**Tegsedi** best fit for Latin American hATTR market

- hATTR polyneuropathy most prevalent phenotype in Latin America
  - ~6,000 patients
- Sub-cutaneous self administration preferable to infusions in the region

**Waylivra**: could utilize our patient support in Latin America

- Similar economic opportunity to Translarna in Latin America
- No other treatments available to treat FCS
- Received EU approval

**FCS** = familial chylomicronemia-syndrome
**FPL** = familial partial lipodystrophy
Building a Leading Rare Disorder Biotech

Leveraging our R&D platforms to continue to grow our pipeline

I. Splicing platform
Leaders in small molecule RNA-splicing technology

Development of SMA candidate as potential best-in-class treatment

13 years of discovering and developing drugs that target pre-mRNA splicing

Cutting-edge tech platform discovered and developed by PTC

2nd Splicing Compound: A Development Candidate to treat Familial Dysautonomia

Continue to exploit Splicing platform; addressing additional areas of unmet need

<table>
<thead>
<tr>
<th>Platform</th>
<th>Mechanism Targeted</th>
<th>Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Splicing</td>
<td>Target-splicing events to restore or decrease protein levels</td>
<td>SMA – SMN2, FD – IKBKAP, HD – HTT, Others</td>
</tr>
</tbody>
</table>
Alternative splicing is governed by interaction of U1 snRNP with canonical and non-canonical exons

- Mostly Canonical Exons
  - Fewer Non-Canonical Exons
  - Weaker interaction requires help to invoke splicing
  - Perfect or near-perfect base pairing to U1

This represents an intervention point where small molecules can assist in modulating splicing
Structure-selectivity-relationships have been developed.

NanoString technology provides EC$_{50}$ values for dozens of splicing changes in a single assay and facilitates selectivity comparisons.
Risdiplam in development for Spinal Muscular Atrophy (SMA)

- Primary genetic cause of infant mortality
- Small molecule promotes the correct splicing of the mutant RNA
- Small molecule has potential for best in class therapy
- Broad tissue distribution and protein restoration

Risdiplam targets splicing events to restore SMN protein levels
Small molecule splicing modifiers

Functional SMN protein created by the SMN2 gene

* Naryshkin et al., Science 2014, ** Palacino et al., Nat Chem Biol 2015
Compound increases SMN protein in multiple tissues to near or above heterozygous levels

Oral dosing for 10 days in mild SMA mouse model

- SMN protein levels in peripheral blood cells correlate to those in brain
- Similar increases in SMN observed in spinal cord, muscle, heart, liver, skin

Naryshkin et al., 2014 Science, 345:688
Risdiplam has potential to be > $2B product

- Revenue > $1B subject to mid-teens* royalty to PTC from Roche
- Potential to PTC to exceed $200M/year; including competitive assumptions for SMA gene therapy
- Firefish & Sunfish fully enrolled
- Risdiplam well tolerated at all doses, no ocular toxicity found in humans

* Revenue estimates based on PTC solely on assumptions
  Full tiered royalty table in press release
The splicing technology is a proven platform to identify new therapeutics

<table>
<thead>
<tr>
<th>Platform</th>
<th>Mechanism Targeted</th>
<th>Programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Splicing</td>
<td>Target-splicing events to restore or decrease protein levels</td>
<td>SMA – SMN2 FD – IKBKAP HD – HTT Others</td>
</tr>
</tbody>
</table>

- Development of SMA candidate as potential best-in-class treatment
- 13 years of discovering and developing drugs that target pre-mRNA splicing
- Cutting-edge tech platform discovered and developed by PTC
- 2nd splicing compound: A development candidate to treat Familial Dysautonomia
- Continue to exploit splicing platform; addressing additional areas of unmet need
Familial dysautonomia:

- Genetic disorder primarily affecting the sensory and autonomic neurons
- Caused by a splicing-altering mutation in the IKBKAP (ELP1) gene resulting in low levels of IKAP protein
- Ashkenazi Jewish ancestry, carrier frequency is ~1:30
- No therapies are currently available for FD, only supportive treatments
- PTC is collaborating with MGH and NYU to advance treatments for FD
Targeting alternative splicing to treat FD

IKBKAP pre-mRNA in FD patients

FL mRNA

Δ20 mRNA

T to C mutation

small molecule stabilization

stabilization

Functional IKAP protein

No IKAP protein

FD phenotype

19

20

21

CAA

guaagc

U1

19

21
Compound increases IKAP protein level in vivo

Ikbkap\(^{+/+}\), IKBKAP TG\(^{FD9}\) mice

Program scheduled to enter the clinic in 2019

Identification of a novel mechanism to lower HTT protein

HTT patient

(CAG)\textgreater{}_{35}

\[ \downarrow \]

Ex 1 → Ex X → Ex Y

Favored mRNA

\[ \downarrow \]

Ex 1 → Ex X → Ex Y

Leads to toxic HTT protein

Mutant toxic HTT protein

(CAG)\textgreater{}_{35}
Splicing modifiers activate a pseudoexon within the HTT mRNA leading to mRNA degradation

**HTT patient**

(CAG)\textgreater{}35

Ex 1 --- Ex X --- Ex Y

Splicing modifier

(CAG)\textgreater{}35

Ex 1 --- Ex X --- Ex Y

Favored mRNA

Leads to toxic HTT protein

Degraded through translation-linked mRNA decay
Splicing modifiers activate a pseudoexon within the HTT mRNA leading to mRNA degradation.

**HTT patient**

\[(\text{CAG})_{\geq 35}\]

\[\text{Ex 1} \quad \text{Ex X} \quad \text{Ex Y}\]

Small molecule assisted exon definition

\[(\text{CAG})_{\geq 35}\]

\[\text{Ex 1} \quad \text{Ex X} \quad \text{Ex Y}\]

**Favored mRNA**

Leads to toxic HTT protein

\[\text{Ex 1} \quad \text{Ex X} \quad \text{Ex Y}\]

Degraded through translation-linked mRNA decay

Mutant toxic HTT protein lowering

\[\text{STOP}\]

\[\text{Ex 1} \quad \text{Ex X} \quad \text{Ex Y}\]
Example of a splicing modifier that targets HTT expression

Splicing modifiers reduce the expression of HTT mRNA and protein

Program scheduled to enter the clinic in 2020
II. A CNS gene therapy platform

Building a Leading Rare Disorder Biotech

Leveraging our R&D platforms to continue to grow our pipeline

II. A CNS gene therapy platform
Platform gene therapy manufacturing advantages

Targeted micro-dosing
- Low doses of vector required
- Efficient, scalable manufacturing
- Low manufacturing hurdles using existing systems

Strategic partnership with MassBiologics Laboratories

Immediate clinical manufacturing capabilities as well as the potential to expand to commercial scale
AADC deficiency is a devastating disease with high unmet need

- Rare progressive childhood disease, affecting approximately 5,000 patients globally
- Children with severe AADC deficiency never achieve motor development milestones
- Profound development failure with shortened life expectancy in severe forms (4 - 8yrs)

GT- AADC: Advanced CNS-delivered gene therapy program

- **Target-delivered gene therapy**
  - Single administration of AAV2-hAADC
  - Low dose \((1.8 \times 10^{11} \text{ vg total})\)
  - Direct delivery using established stereotactic surgery

- **Clinically durable effect in patients**
  - First patients treated in 2010
  - Three clinical studies with safety data in 26 patients
  - Functional improvements on validated scales
  - Significant and durable gains in major motor development milestones

GT-AADC: Significant & durable motor improvements

1-Year Results of Motor Development
PDMS-21 through 12 months – Studies 1 & 2

5-Year Results of Motor Development
PDMS-21 through 60 months - Study 1

1 Peabody Developmental Motor Scale
Patient identification is our expertise

- Earlier diagnosis
- Increase disease awareness
- Genotyping
- Improving standards of care

~100 AADC patients already identified in the US and Europe
- Genotyping patients in seizure and cerebral palsy clinics
- Plan to screen >100K at-risk patients for AADC
Most advanced FA gene therapy program

PTC plans to submit IND in 2019

- Targeted Micro dosing / direct to CNS
- Favorable immunogenic profile
- Animal data supports appropriate dose
- Patient group engagement
Friedreich Ataxia (FA) is a severe neuromuscular disorder amenable to gene therapy

- Inherited, monogenic disease arising from triplet repeat expansion
- Mutation in frataxin gene limits protein production

- Most common hereditary ataxia (~25,000 patients globally)
- Childhood onset
- Debilitating, life shortening neuromuscular disorder
- Only palliative treatments available currently
Moving toward IND submission in 2019

PTC-FA Intracerebellar Dosing in Porcine Model*

Unilateral dose of $3.0 \times 10^{12}$ vg total - Day 28 Mean (SEM)
*Human-specific detection

PTC-FA Intracerebellar Dosing in NHP Model*

Bi-lateral Dose of $2.4 \times 10^{12}$ vg total - Day 28 - Mean (SEM)
*NHP background subtracted
Potential addressable market in excess of $5B

- **AADC:** Aromatic L-amino acid decarboxylase
- **FA:** Friedreich ataxia
- **AS:** Angelman syndrome

Launch Sequence

- **AADC deficiency:** ~5,000 patients
- **AADC & FA:** ~30,000 patients
- **AADC, FA, & AS:** ~100,000 patients
Sustainable growth expected over next 5 years
Potential revenues to PTC from DMD franchise, Gene therapy programs, Tegsedi and Risdiplam

2019
- Expected SMA milestones for regulatory filings, Emflaza 2-5 launch

2020
- Potential Tegsedi, SMA, AADC and Translarna US launches

2021
- Potential Emflaza Limb-Girdle 2i launch

2022

2023

2024